Document registry — page 23
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body…
High23 May 2025 -
Determination of water content in lyophilised peptides by coulometric Karl Fischer titration
High23 May 2025 -
Single-arm open-label, phase 3 study of Orforglipron in obesity and type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported…
Very low23 May 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in peripheral arterial disease and type 2 diabetes over as stated in the parent protocol. The…
Very low23 May 2025 -
Consultation on the draft monograph for TB-500, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
22 May 2025 -
What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?
Moderate20 May 2025 -
GIP receptor antagonist and GLP-1 receptor agonist conjugate (antibody–peptide). GLP-1 receptor agonism supplies appetite suppression; GIP receptor antagonism is proposed to act on adipose tissue and central pathways in…
Low19 May 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the…
Moderate17 May 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the incidence of adverse events leading to discontinuation with SS-31…
Moderate14 May 2025 -
Randomised, double-blind, placebo-controlled study of DSIP in sleep over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 May 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Survodutide in obesity randomising 387 participants over 46 weeks. Primary result: Mean change −18.7 % at…
Moderate12 May 2025 -
Observational study of Semax in cognition over not recorded. Primary result: As above. The Institute grades all claims for this compound very low certainty for absence…
12 May 2025 -
Research-catalogue peptides, SARMs, injectable oils and raw materials, synthesised in house by Fmoc solid-phase methods.
11 May 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its…
High08 May 2025 -
Phase 1 ascending dose, phase 1 study of Amycretin in obesity randomising 125 participants over up to 36 weeks. Primary result: Exploratory weight reduction of…
Low04 May 2025 -
Consultation on the print and archival format for Institute documents: what a printed copy must carry so that it remains checkable when detached from the site, and what…
02 May 2025 -
Consultation on the terms governing the Institute's calculators. The draft states that a calculator implements a published formula, that it holds no user data, and that…
01 May 2025 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over 52 weeks. Primary result: Directionally consistent with the…
High24 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no…
Very low24 Apr 2025 -
Consultation on the draft of this scoping review, which registers the question: What randomised human evidence exists for BPC-157 in any indication?
22 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults at elevated cardiovascular risk, what is the effect of a glucagon-like…
20 Apr 2025 -
Long-acting amylin analogue. Amylin receptor agonism at the area postrema promoting meal-related satiation, with a formulation and half-life supporting weekly dosing. The…
Low20 Apr 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the anchor…
Moderate18 Apr 2025 -
Mitochondria-targeted cardiolipin-binding tetrapeptide. Elamipretide binds cardiolipin in the inner mitochondrial membrane, stabilising cristae curvature and the assembly of electron-transport-chain…
Moderate17 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tirzepatide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Apr 2025 -
Consultation on the draft of this intervention review, which registers the question: In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and…
16 Apr 2025 -
Consultation on the draft of CEI-MS-06, which specifies the performance a determination must achieve for microbiological quality and states what the resulting figure…
14 Apr 2025 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its…
Moderate14 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 2 study of BPC-157 in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary…
Very low13 Apr 2025 -
GLP-1 receptor agonist (exendin-based, short-acting). A short-acting prandial GLP-1 receptor agonist. Its dominant pharmacodynamic effect is marked slowing of gastric emptying, which produces substantial…
Moderate12 Apr 2025 -
What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a…
Moderate11 Apr 2025 -
Observational, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low09 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity randomising 731 participants over median 104 weeks. Primary result…
Moderate07 Apr 2025 -
Phase 1 ascending dose, phase 1 study of Gonadorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Apr 2025 -
Consultation on the third version of the semaglutide monograph. The revision incorporates the cardiovascular outcome evidence from SELECT, reported in the New England…
03 Apr 2025 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported…
Very low31 Mar 2025 -
Consultation on the draft monograph for GHRP-2, which the assessment committee released for public comment before ratification. The draft grades the compound's principal…
30 Mar 2025 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1…
Moderate30 Mar 2025 -
Consultation on the draft of this safety review, which registers the question: What is the incidence of gastrointestinal adverse events and of discontinuation for…
29 Mar 2025
page 23 of 41